February 8, 2016
MiMedx Group Inc. recently announced it has completed the acquisition of Stability Biologics, a provider of human tissue products to surgeons and facilities. Under the deal, Stability Biologics will operate as a wholly owned subsidiary of MiMedx.
The transaction was originally announced on Jan. 10, 2016, according to a press release from MiMedx. MiMedx confirmed the closing consideration for the transaction was $10 million paid at closing, comprised of 60% cash and 40% stock. MiMedx noted the transaction also included assumed debt with future contingent consideration to be paid through a 2-year earn out arrangement based on the 2016 and 2017 performance of Stability Biologics.